OBJECTIVE: Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS: We leveraged the International Study of Inflammation in COVID-19 (ISIC), a multicenter observational study of 2,044 patients hospitalized with COVID-19, to characterize the impact of DM on in-hospital outcomes and assess the contribution of inflammation and hyperglycemia to the risk attributed to DM. We measured biomarkers of inflammation collected at hospital admission and collected glucose levels and insulin data throughout hospitalization. The primary outcome was the composite of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. RESULTS: Among participants (mean age 60 years, 58.2% males), those with DM (n = 686, 33.5%) had a significantly higher cumulative incidence of the primary outcome (37.8% vs. 28.6%) and higher levels of inflammatory biomarkers than those without DM. Among biomarkers, DM was only associated with higher soluble urokinase plasminogen activator receptor (suPAR) levels in multivariable analysis. Adjusting for suPAR levels abrogated the association between DM and the primary outcome (adjusted odds ratio 1.23 [95% CI 0.78, 1.37]). In mediation analysis, we estimated the proportion of the effect of DM on the primary outcome mediated by suPAR at 84.2%. Hyperglycemia and higher insulin doses were independent predictors of the primary outcome, with effect sizes unaffected by adjusting for suPAR levels. CONCLUSIONS: Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyperinflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.
OBJECTIVE: Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS: We leveraged the International Study of Inflammation in COVID-19 (ISIC), a multicenter observational study of 2,044 patients hospitalized with COVID-19, to characterize the impact of DM on in-hospital outcomes and assess the contribution of inflammation and hyperglycemia to the risk attributed to DM. We measured biomarkers of inflammation collected at hospital admission and collected glucose levels and insulin data throughout hospitalization. The primary outcome was the composite of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. RESULTS: Among participants (mean age 60 years, 58.2% males), those with DM (n = 686, 33.5%) had a significantly higher cumulative incidence of the primary outcome (37.8% vs. 28.6%) and higher levels of inflammatory biomarkers than those without DM. Among biomarkers, DM was only associated with higher soluble urokinase plasminogen activator receptor (suPAR) levels in multivariable analysis. Adjusting for suPAR levels abrogated the association between DM and the primary outcome (adjusted odds ratio 1.23 [95% CI 0.78, 1.37]). In mediation analysis, we estimated the proportion of the effect of DM on the primary outcome mediated by suPAR at 84.2%. Hyperglycemia and higher insulin doses were independent predictors of the primary outcome, with effect sizes unaffected by adjusting for suPAR levels. CONCLUSIONS: Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyperinflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: J Eugen-Olsen; O Andersen; A Linneberg; S Ladelund; T W Hansen; A Langkilde; J Petersen; T Pielak; L N Møller; J Jeppesen; S Lyngbaek; M Fenger; M H Olsen; P R Hildebrandt; K Borch-Johnsen; T Jørgensen; S B Haugaard Journal: J Intern Med Date: 2010-05-28 Impact factor: 8.989
Authors: A Heraclides; T M Jensen; S S Rasmussen; J Eugen-Olsen; S B Haugaard; K Borch-Johnsen; A Sandbæk; T Lauritzen; D R Witte Journal: Diabetologia Date: 2013-04-24 Impact factor: 10.122
Authors: Salim S Hayek; Sanja Sever; Yi-An Ko; Howard Trachtman; Mosaab Awad; Shikha Wadhwani; Mehmet M Altintas; Changli Wei; Anna L Hotton; Audrey L French; Laurence S Sperling; Stamatios Lerakis; Arshed A Quyyumi; Jochen Reiser Journal: N Engl J Med Date: 2015-11-05 Impact factor: 91.245
Authors: Francisco Javier Carrasco-Sánchez; Mª Dolores López-Carmona; Francisco Javier Martínez-Marcos; Luis M Pérez-Belmonte; Alicia Hidalgo-Jiménez; Verónica Buonaiuto; Carmen Suárez Fernández; Santiago Jesús Freire Castro; Davide Luordo; Paula Maria Pesqueira Fontan; Julio César Blázquez Encinar; Jeffrey Oskar Magallanes Gamboa; Andrés de la Peña Fernández; José David Torres Peña; Joaquim Fernández Solà; Jose Javier Napal Lecumberri; Francisco Amorós Martínez; María Esther Guisado Espartero; Carlos Jorge Ripper; Raquel Gómez Méndez; Natalia Vicente López; Berta Román Bernal; María Gloria Rojano Rivero; José Manuel Ramos Rincón; Ricardo Gómez Huelgas Journal: Ann Med Date: 2021-12 Impact factor: 4.709
Authors: Markus Bitzer; Wenjun Ju; Lalita Subramanian; Jonathan P Troost; Joseph Tychewicz; Becky Steck; Roger C Wiggins; Debbie S Gipson; Crystal A Gadegbeku; Frank C Brosius; Matthias Kretzler; Subramaniam Pennathur Journal: Am J Physiol Renal Physiol Date: 2022-08-04
Authors: Moussa A Riachy; Anis Ismail; Mohamad Awali; Fadi Farah; Sara F Haddad; Anthony Kerbage; Noel Aoun; Ghassan Sleilaty Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2022-07-21
Authors: Catia Cilloniz; Juan M Pericàs; Anna Motos; Albert Gabarrús; Ricard Ferrer; Rosario Menéndez; Jordi Riera; Dario García-Gasulla; Oscar Peñuelas; Laia Fernández-Barat; José Ángel Lorente; David de Gonzalo-Calvo; Ferran Barbé; Antoni Torres Journal: Arch Bronconeumol Date: 2022-09-09 Impact factor: 6.333